H2020-JTI-IMI2-2017-12-two-stage
H2020-JTI-IMI2-2017-12-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 7
- EU contribution (sum)
- €64,051,532
- Portal deadline
- —
Leading topic in historical projects: IMI2-2017-12-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- ERASMUS MC1 coordinated
- EMBL1 coordinated
- INSERM1 coordinated
- KING'S COLLEGE LONDON1 coordinated
- FOUNDATION LYGATURE1 coordinated
- UOXF1 coordinated
- UMC UTRECHT1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- NOVARTIS3 topic projects
- ELI LILLY AND COMPANY LTD2 topic projects
- Fraunhofer2 topic projects
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED2 topic projects
- JANSSEN PHARMACEUTICA NV2 topic projects
- KI2 topic projects
- THE HYVE2 topic projects
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 topic projects
- AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN1 topic projects
- ALTOIDA SA ALTOIDA LTD1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- JANSSEN PHARMACEUTICA NV · UOXF5 shared
BE ↔ UK
- 4 shared
- JANSSEN PHARMACEUTICA NV · NOVARTIS4 shared
BE ↔ CH
- UOXF · ASTRAZENECA AB3 shared
UK ↔ SE
- FOUNDATION LYGATURE · UOXF3 shared
NL ↔ UK
- ELI LILLY AND COMPANY LTD · UOXF3 shared
UK ↔ UK
- BAYER AKTIENGESELLSCHAFT · ASTRAZENECA AB3 shared
DE ↔ SE
- THE HYVE · ELI LILLY AND COMPANY LTD3 shared
NL ↔ UK
- 3 shared
- BAYER AKTIENGESELLSCHAFT · UOXF3 shared
DE ↔ UK
- 3 shared
- JANSSEN PHARMACEUTICA NV · ASTRAZENECA AB3 shared
BE ↔ SE
- 3 shared
- JANSSEN PHARMACEUTICA NV · THE HYVE3 shared
BE ↔ NL
- 3 shared
- NOVARTIS · ELI LILLY AND COMPANY LTD3 shared
CH ↔ UK
- 3 shared
- JANSSEN PHARMACEUTICA NV · SARD2 shared
BE ↔ FR
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 23.57
- Median orgs / project
- 25
- Min / max orgs
- 17 – 29
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- United Kingdom33
- France23
- Netherlands23
- Germany18
- Switzerland11
- Belgium11
- Spain7
- Sweden7
- Denmark6
- Italy5
- United States4
- Norway3
- Austria3
- Luxembourg2
- Greece2
- Hungary2
- Czechia1
- Estonia1
Organization types
- company32 orgs · 54 rows
- university42 orgs · 51 rows
- research_institute28 orgs · 32 rows
- sme16 orgs · 18 rows
- other6 orgs · 8 rows
- public_body2 orgs · 2 rows
Topics in funded projects
- IMI2-2017-12-01IMI2-2017-12-01· 1 projects
- IMI2-2017-12-02IMI2-2017-12-02· 1 projects
- IMI2-2017-12-03IMI2-2017-12-03· 1 projects
- IMI2-2017-12-04IMI2-2017-12-04· 1 projects
- IMI2-2017-12-05IMI2-2017-12-05· 1 projects
- IMI2-2017-12-06IMI2-2017-12-06· 1 projects
- IMI2-2017-12-07IMI2-2017-12-07· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| ESCulab European Screening Centre; Unique Library for Attractive Biology | H2020 | €18,249,993 |
| EHDEN European Health Data and Evidence Network | H2020 | €14,105,750 |
| IM2PACT Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain | H2020 | €9,000,000 |
| NECESSITY NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients | H2020 | €8,200,000 |
| VITAL Vaccines and Infectious Diseases in the Ageing PopuLation | H2020 | €5,499,882 |
| RADAR-AD Remote Assessment of Disease and Relapse – Alzheimer’s Disease | H2020 | €4,999,757 |
| FAIRplus FAIRplus | H2020 | €3,996,150 |